Revance Therapeutics Inc (RVNC)
2.71
+0.04
(+1.50%)
USD |
NASDAQ |
May 24, 16:00
2.70
-0.01
(-0.37%)
After-Hours: 20:00
Revance Therapeutics Cash and Short Term Investments (Quarterly): 277.07M for March 31, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 277.07M |
| December 31, 2023 | 253.92M |
| September 30, 2023 | 300.24M |
| June 30, 2023 | 319.72M |
| March 31, 2023 | 273.95M |
| December 31, 2022 | 340.71M |
| September 30, 2022 | 378.63M |
| June 30, 2022 | 233.82M |
| March 31, 2022 | 262.59M |
| December 31, 2021 | 225.07M |
| September 30, 2021 | 273.68M |
| June 30, 2021 | 336.30M |
| March 31, 2021 | 386.81M |
| December 31, 2020 | 436.50M |
| September 30, 2020 | 435.83M |
| June 30, 2020 | 494.04M |
| March 31, 2020 | 511.27M |
| December 31, 2019 | 290.12M |
| September 30, 2019 | 209.03M |
| June 30, 2019 | 241.89M |
| March 31, 2019 | 270.99M |
| December 31, 2018 | 175.81M |
| Date | Value |
|---|---|
| September 30, 2018 | 208.39M |
| June 30, 2018 | 233.73M |
| March 31, 2018 | 268.81M |
| December 31, 2017 | 282.90M |
| September 30, 2017 | 153.44M |
| June 30, 2017 | 165.54M |
| March 31, 2017 | 188.64M |
| December 31, 2016 | 185.53M |
| September 30, 2016 | 201.25M |
| June 30, 2016 | 216.94M |
| March 31, 2016 | 236.61M |
| December 31, 2015 | 252.30M |
| September 30, 2015 | 141.86M |
| June 30, 2015 | 135.30M |
| March 31, 2015 | 153.72M |
| December 31, 2014 | 171.03M |
| September 30, 2014 | 187.49M |
| June 30, 2014 | 203.31M |
| March 31, 2014 | 87.85M |
| December 31, 2013 | 3.914M |
| September 30, 2013 | 1.909M |
| December 31, 2012 | 4.083M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
209.03M
Minimum
Sep 2019
511.27M
Maximum
Mar 2020
324.06M
Average
295.18M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| AbbVie Inc | 18.07B |
| Eli Lilly and Co | 2.586B |
| Aquestive Therapeutics Inc | 95.20M |
| Humacyte Inc | 115.50M |
| AN2 Therapeutics Inc | 114.21M |